StockData
Tempest Therapeutics, Inc. logo

Tempest Therapeutics, Inc. (TPST) stock

TPSTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 4/30
$0.31−0.02 (-5.50%)

Close on Nov 18, 2026Market cap $4.58MP/E –Yield –

Tempest Therapeutics gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

Tempest Therapeutics's gross profit for the twelve months ending Sep 30, 2018 was -$134.00K. For fiscal 2017 it was -$495.00K. The highest annual figure on record is $0 in fiscal 2013.

Annual gross profit

PeriodPeriod endValueChange
FY2017Dec 31, 2017-$495.00K–
FY2016Dec 31, 2016-$4.75M–
FY2015Dec 31, 2015-$1.97M–
FY2014Dec 31, 2014$0–
FY2013Dec 31, 2013$0–

Quarterly gross profit

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2018Sep 30, 2018$11.00K-59.3%
Q2 FY2018Jun 30, 2018$27.00K–
Q1 FY2018Mar 31, 2018-$45.00K–
Q4 FY2017Dec 31, 2017-$127.00K–
Q3 FY2017Sep 30, 2017$27.00K–
Q2 FY2017Jun 30, 2017-$190.00K–
Q1 FY2017Mar 31, 2017-$206.00K–
Q4 FY2016Dec 31, 2016-$1.31M–
Q3 FY2016Sep 30, 2016-$1.36M–

More Tempest Therapeutics figures

See a number that looks wrong?